Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed-Carboplatin vs Docetaxel-Carboplatin in First-Line NSCLC
NCT00520676Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2007
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Oct 2007; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00520676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520676.